Read our Recent Headlines

April 28 Biotech Update

A lot has happened in terms of news in the sector, although there is nothing that was thesis changing. There are some new potential trends to watch but at this.

April 26 Biotech Update

Today is the eye in the center of the storm with a number of earnings tomorrow. It might also be the eye in the center of the North Korean crisis.

April 25 Biotech Update

The market continues to have a tail wind as France and North Korean risks are being removed (although not sure we are quite out of the woods on North Korea.

April 24 Biotech Update

The market is surging and is dragging the sector higher with it. It seems to me that the sector is not doing particularly well given the new risk on environment.

April 19 Biotech Update

The sector is not doing well. The broader market is getting stronger and biotech cannot seem to catch a bid or hold any sort of gain. Volume is anemic. All.

April 18 Biotech Update

Nothing dramatically new happening in the sector. There are a couple of interesting tidbits that are worth talking about but certainly no thesis changing or confirming news. 1. JNJ started.

Dave-Trading – May 2017

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!